The "Fast Money" traders debated whether it's time to pile into the biotech sector after the sector gained 3 percent on Monday.
The "Fast Money" traders give you 5 trades in biotech.
Aside from the financial crisis, health care hasn't lagged the broader market this badly since Bill Clinton was president.
The "Fast Money Halftime Report" traders and Stephanie Link, TIAA Global Asset Management, take their positions on four stocks making news today, including Goodyear Tire, Mondelez and more.
With biotechs in the political crosshairs, is now the time to look at the space? With Michael Yee, RBC Capital biotech analyst.
Biotech stocks have underperformed the market but that could change as investors bet more deals could be in the making.
CNBC's Meg Tirrell reports the latest details on Valeant and its potential criminal probe. The "Fast Money Halftime Report" traders and Yana Barton, Eaton Vance portfolio manager, add perspective.
Wharton professor Jeremy Siegel predicted that the market would rally, here's what he sees next.
Endo International shares surged after it posted second-quarter earnings that exceeded analysts expectations and appointed new management.
Jim Cramer outlined the stocks and events he will be watching next week, and has his eye on one cohort.
Biotech stocks have seen a big bounce in the past few weeks, as the group hits its highest level since January. Talking biotech, with David Seaburg, Cowen, and Chad Morganlander, Stifel Nicolaus.
CNBC's Landon Dowdy takes a look at the best performing sectors and stocks in the S&P 500 this summer so far.
Jim Cramer identified four groups to embrace and avoid in the market, including one with a powerful growth story.
The $75 billion Biogen may be vulnerable to a takeover, but it makes a risky target at a likely value approaching $90 billion.
CNBC's Tyler Mathisen looks at good, bad and ugly stocks, including Biogen, Qorvo and more.
Biotech hits a 6-month high. The "Fast Money Halftime Report" traders discusses whether they think it's time to buy biotech.
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell.
Ronny Gal, Sanford C. Bernstein, discusses the potential of a takeover deal for Biogen.
Barbara Ryan, Partner at Barbra Ryan Advisors, discusses the biotech and pharma space as rumors fly on a takeover deal for Biogen.
Geoff Porges, Leerink Partners Managing Director & Senior Biotech Analyst, discusses the news that Biogen is a possible takeover target for the likes of Merck and Allergan.